版本:
中国

BRIEF-Rigel announces Tavaliss as proprietary name for Fostamatinib in the U.S.

April 27 Rigel Pharmaceuticals Inc:

* Rigel announces Tavalisse™ as proprietary name for Fostamatinib in the united states

* Says in addition, Rigel has applied to u.s. Patent and trademark office to obtain federal registration of tavalisse mark

* Rigel pharmaceuticals inc - Rigel has applied to u.s. Patent and trademark office to obtain federal registration of tavalisse mark Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐